Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First in man study of FLYSYN in AML patients with minimal residual disease
DRKS00011887Phase 2Completed
- Sponsor
- Synimmune
- Start
- Mar 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of FLYSYN in acute myeloid leukemia (AML) (6 cohorts), sponsored by Synimmune. Primary endpoints: Safety and tolerability of FLYSYN and Preliminary efficacy of FLYSYN. Started Mar 2017; status: completed.
02
Drugs
FLYSYN
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on DRKS00011887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00011887.